Syapse combines clinical expertise with smart technologies to transform data into evidence and experience in collaboration with a network of partners. The company is led by CEO Ken Tarkoff and is based in San Francisco and New York. Its core offering includes a Learning Health Network that partners with community health systems to support precision medicine strategies aimed at improving clinical outcomes, reducing costs, and enhancing patient experience. Syapse has also added life sciences partnerships with established biopharmaceutical companies. The company raised $35M in Growth funding and intends to use the funds to expand its focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer. Syapse provides real-world evidence (RWE) and actionable treatment insights through its Syapse Learning Health Network to improve outcomes for people with cancer. The platform standardizes and normalizes de-identified clinical and molecular data across participating healthcare providers to support clinical decisions and research. Syapse has expanded partnerships with community health systems and life sciences companies and has collaborated with the FDA to address urgent public health challenges, including COVID-19. The company positions its network to drive precision medicine strategies that aim to improve clinical outcomes, reduce costs, and enhance patient experience. The announced financing is intended to expand partnering opportunities with life sciences, health systems, regulators, and molecular labs to deliver more real-world insights. Syapse works with leading health systems, life sciences companies, and regulators to accelerate the creation and use of real-world evidence to improve cancer patient outcomes. The company provides insights from real-world data through a portfolio of products that support research and product development, clinical trial patient matching, regulatory filings, and monitoring of commercially approved products. Syapse integrates clinical, molecular, and outcomes data to support large‑scale precision medicine programs at health systems. Its Syapse Learning Health Network is described in the press release as one of the world’s largest networks dedicated to improving outcomes in cancer care through precision medicine. The company recently presented collaborative research with the FDA Office of Clinical Pharmacology and Advocate Aurora Health on pneumonitis incidence at the AACR annual meeting, illustrating its RWE capabilities. Proceeds from the announced financing are intended to accelerate the creation and use of real‑world evidence in oncology and support Syapse’s ongoing collaborations and product development. Syapse develops an oncology software platform and the Syapse Data Sharing Network to enable physicians to view treatments and outcomes for patients across the country and apply that information to improve care. Led by CEO Ken Tarkoff and based in San Francisco, the company sells its platform to large health systems and lists customers including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health. Syapse recently raised $30m in Series D financing. The company intends to use the funds to expand operations and bring its solutions to more providers and their cancer patients. Its core product focuses on enabling consistent precision-medicine practice across large health systems by connecting treatment and outcome data. The Data Sharing Network is positioned as a clinical-data tool to inform treatment decisions across participating institutions. Syapse provides cloud-based precision medicine software to academic and community health systems to support widespread adoption of precision oncology. The platform integrates clinical, genomic, and other molecular data from medical records, labs, and pharmacies to create a longitudinal patient profile. It offers guidance on diagnostic and therapeutic strategy based on clinical best practices and supports implementation of treatment decisions while coordinating care across geographically dispersed teams. The software also measures patient outcomes to learn what works and improve best practices. Led by CEO Glenn Winokur and based in Palo Alto, Syapse intends to use new funding to expand adoption of its software in community health systems. The company completed the first close of a Series C financing as reported in December 2016.

Total raised

$201M

Funding rounds

7

Latest round

Equity

Latest activity

Jul 2022